What is the 13F Pro Quality Score for SCLX?

13F Pro ranks Scilex Holding Co (SCLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SCLX's current score at https://13fpro.ai/research/SCLX (free sign-up required for the full ranking).

Which hedge funds own the most SCLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SCLX include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SCLX as soon as new 13F filings post.

Where does 13F Pro source SCLX data?

All Scilex Holding Co fundamentals and ownership data come directly from SEC EDGAR. Scilex Holding Co files with the SEC under CIK 1820190. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SCLX in?

Scilex Holding Co (SCLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SCLX research updated on 13F Pro?

SCLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Scilex Holding Co(SCLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1820190 SCLX stock profile & AI dashboard →

13F Pro Quality Score

20.5/100

Rank #2,672 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

10.8/100

Profitability

2.3/100

Balance Sheet

0.7/100

Earnings Quality

30.0/100

Free Cash Flow

94.2/100

Institutional Flow

13.5/100

Revenue Scale

8.4/100

Dilution Risk

4.6/100

SCLX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Scilex Holding Co (SCLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SCLX at 20.5/100 on a 32-signal composite quality model, placing it at rank #2,672 of 2,879 stocks — the bottom half of the AI-ranked universe. SCLX scores in the top quartile across free cash flow (94.2). Areas of concern include balance sheet strength (0.7) and profitability (2.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Scilex Holding Co reports quarterly revenue of $8.6M, net income of $-45.6M, free cash flow of $-1.1M. Top institutional holders of SCLX by reported 13-F value include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, BlackRock,, based on the most recent SEC filings. SCLX trades on the Nasdaq exchange and files with the SEC under CIK 1820190. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Scilex Holding Co directly from SEC EDGAR. Scilex Holding Co's 13F Pro composite quality score has ranged between 12 and 40 since 2023, currently 20.5 — a declining long-term trajectory across 20 quarterly and live scoring snapshots.

✦

Fun facts about Scilex Holding Co

Quirks, history, and lore behind SCLX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · focused on non-opioid pain management.
2
The Numbers
Revenues in the tens of millions of dollars annually — a commercial-stage biotech still working toward profitability in a market worth billions.
3
The History
The company traces its roots to a spin-off from Sorrento Therapeutics, going public as an independent entity in the early 2020s.
4
The Secret
Its commercial focus is a long-acting injectable local anesthetic — a product designed to keep patients comfortable for days after surgery without addictive opioids.
5
The Lore
Its lead product, ZTlido, is a lidocaine patch for post-shingles nerve pain — and the company has been building a pipeline of lidocaine-based therapies across multiple pain indications.
6
The Giveaway
Ticker SCLX, born from Sorrento, betting that non-addictive pain relief can win over a healthcare world desperate to move past the opioid crisis.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.6M

Net Income

Q1 2026

$-45.6M

Free Cash Flow

Q1 2026

$-1.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+21.1% YoY

$56.6MFY 2024

FY21 $31.3MFY22 $38.0MFY23 $46.7MFY24 $56.6M

Net Income

+36.3% YoY

$-72.8MFY 2024

FY21 $-88.4MFY22 $-23.4MFY23 $-114.3MFY24 $-72.8M

Operating Income

+20.9% YoY

$-83.4MFY 2024

FY21 $-35.8MFY22 $-50.6MFY23 $-105.4MFY24 $-83.4M

EPS (Diluted)

-528.9% YoY

$-8.05FY 2024

FY21 $-0.02FY22 $-0.17FY23 $-1.28FY24 $-8.05

Total Assets

-8.2% YoY

$93.0MFY 2024

FY21 $139.9MFY22 $86.5MFY23 $101.3MFY24 $93.0M

Total Debt

-67.8% YoY

$34.9MFY 2024

FY21 $139.1MFY22 $0.00FY23 $108.4MFY24 $34.9M

Op. Cash Flow

+193.4% YoY

$19.3MFY 2024

FY21 $-28.7MFY22 $-21.3MFY23 $-20.7MFY24 $19.3M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$56.6M +21.1%	$46.7M +22.9%	$38.0M +21.4%	$31.3M	—
Net Income	$-72.8M +36.3%	$-114.3M -389.3%	$-23.4M +73.6%	$-88.4M	—
Operating Income	$-83.4M +20.9%	$-105.4M -108.2%	$-50.6M -41.3%	$-35.8M	—
EPS (Diluted)	$-8.05 -528.9%	$-1.28 -652.9%	$-0.17 -942.9%	$-0.02	—
Total Assets	$93.0M -8.2%	$101.3M +17.1%	$86.5M -38.2%	$139.9M	—
Total Debt	$34.9M -67.8%	$108.4M	$0.00 -100.0%	$139.1M	—
Operating Cash Flow	$19.3M +193.4%	$-20.7M +2.6%	$-21.3M +25.8%	$-28.7M	—

AI Insight: SCLX Financial Trends

Scilex is in financial distress with collapsing revenue, persistent operating losses, and deteriorating cash generation.

• Revenue halved from $16M (Q2 2024) to $9M (Q1 2026), with no recovery trajectory evident across 8 quarters.

• Operating cash flow turned negative in Q4 2025 (−$17M) and remained negative in Q1 2026 (−$1M) after positive flow prior.

• Total debt rose from $35M (Q4 2024 low) to $83M (Q4 2025), while equity remained deeply negative (−$249M in Q1 2026).

⚠ Q3 2025 saw a $258M net loss spike (vs. typical −$26M to −$6M), suggesting a one-time charge or impairment; sustainability unclear.

⚠ Operating losses widened dramatically in Q3–Q4 2025 (−$187M, −$111M) before partial recovery to −$32M in Q1 2026.

AI Insight: SCLX Ratio Trends

Scilex deteriorated sharply through 2024 with operating margins collapsing to -190.5% in Q4 2024, followed by accelerating ROA declines into Q1 2026 at -62.2%.

• Operating margin swung from -95.4% (Q2 2024) to -190.5% (Q4 2024), signaling deepening operational losses.

• Net profit margin deteriorated to -43.4% in Q4 2024, indicating severe bottom-line pressure.

• ROA worsened from -17.5% (Q3 2024) to -62.2% (Q1 2026), reflecting mounting asset efficiency collapse.

⚠ ROA contraction accelerated post-Q4 2024 (-27.8% to -62.2%), suggesting deteriorating fundamentals persist into 2026.

⚠ Data gaps across 2025 Q1–Q3 and missing profitability metrics for recent quarters limit visibility into recovery trajectory.

Get alerted when SCLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Scilex Holding Co including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SCLX

ARMISTICE CAPITAL, LLC
$2.0M297,706 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.8M264,050 sh
BlackRock, Inc.
$684.6K102,796 sh
VANGUARD FIDUCIARY TRUST CO
$264.1K39,658 sh
RENAISSANCE TECHNOLOGIES LLC
$245.5K36,864 sh
STATE STREET CORP
$235.6K35,376 sh
XTX Topco Ltd
$150.6K22,606 sh
Ashton Thomas Private Wealth, LLC
$119.8K17,989 sh
NORTHERN TRUST CORP
$100.1K15,033 sh
MORGAN STANLEY
$79.7K11,973 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$2.0M	297,706
VANGUARD CAPITAL MANAGEMENT LLC	$1.8M	264,050
BlackRock, Inc.	$684.6K	102,796
VANGUARD FIDUCIARY TRUST CO	$264.1K	39,658
RENAISSANCE TECHNOLOGIES LLC	$245.5K	36,864
STATE STREET CORP	$235.6K	35,376
XTX Topco Ltd	$150.6K	22,606
Ashton Thomas Private Wealth, LLC	$119.8K	17,989
NORTHERN TRUST CORP	$100.1K	15,033
MORGAN STANLEY	$79.7K	11,973

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SCLX on your watchlist

Track score changes the day Scilex Holding Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SCLX a good stock to buy?

13F Pro's AI-powered analysis of Scilex Holding Co (SCLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCLX are available on the SCLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SCLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Scilex Holding Co's investment landscape.